FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783176674> ?p ?o ?g. }

• W2783176674 endingPage "532" @default.
• W2783176674 startingPage "529" @default.
• W2783176674 abstract "Essentials•The prevalence of thrombocytopenia in patients with antiphospholipid syndrome is not well defined.•We studied triple positive patients with antiphospholipid syndrome and its catastrophic variant.•Prevalence of thrombocytopenia was 6% and 100% in patients who developed the catastrophic form.•In triple positive patients thrombocytopenia is low and platelets drop during the catastrophic form.Summary: BackgroundThrombocytopenia is the most common non‐criteria hematological feature in patients with antiphospholipid syndrome (APS). This condition is more common in patients with catastrophic APS (CAPS).ObjectivesTo evaluate the prevalence of thrombocytopenia in a large series of high‐risk patients with APS, and to assess the behavior of the platelet count during CAPS.Methods/PatientsThis was a cross‐sectional study in which we analyzed the platelet counts of a homogeneous group of high‐risk APS patients (triple‐positive). Six of these patients developed a catastrophic phase of the disease, and the platelet count was recorded before the acute phase, during the acute phase, and at recovery.ResultsThe mean platelet count in 119 high‐risk triple‐positive patients was 210 × 109 L−1. With a cut‐off value for thrombocytopenia of 100 × 109 L−1, the prevalence of thrombocytopenia was 6% (seven patients). No difference between primary APS and secondary APS was found. In patients who suffered from CAPS, a significant decrease from the basal count (212 ± 51 × 109 L−1) to that at the time of diagnosis (60 ± 33 × 109 L−1) was observed. The platelet count became normal again at the time of complete remission (220 ± 57 × 109 L−1). A decrease in platelet count always preceded the full clinical picture.ConclusionsThis study shows that, in high‐risk APS patients, the prevalence of thrombocytopenia is low. A decrease in platelet count was observed in all of the patients who developed the catastrophic form of the disease. A decrease in platelet count in high‐risk APS patients should be considered a warning signal for disease progression to CAPS. Essentials•The prevalence of thrombocytopenia in patients with antiphospholipid syndrome is not well defined.•We studied triple positive patients with antiphospholipid syndrome and its catastrophic variant.•Prevalence of thrombocytopenia was 6% and 100% in patients who developed the catastrophic form.•In triple positive patients thrombocytopenia is low and platelets drop during the catastrophic form. •The prevalence of thrombocytopenia in patients with antiphospholipid syndrome is not well defined.•We studied triple positive patients with antiphospholipid syndrome and its catastrophic variant.•Prevalence of thrombocytopenia was 6% and 100% in patients who developed the catastrophic form.•In triple positive patients thrombocytopenia is low and platelets drop during the catastrophic form. Thrombocytopenia is the most common non‐criteria hematological feature in patients with antiphospholipid syndrome (APS). This condition is more common in patients with catastrophic APS (CAPS). To evaluate the prevalence of thrombocytopenia in a large series of high‐risk patients with APS, and to assess the behavior of the platelet count during CAPS. This was a cross‐sectional study in which we analyzed the platelet counts of a homogeneous group of high‐risk APS patients (triple‐positive). Six of these patients developed a catastrophic phase of the disease, and the platelet count was recorded before the acute phase, during the acute phase, and at recovery. The mean platelet count in 119 high‐risk triple‐positive patients was 210 × 109 L−1. With a cut‐off value for thrombocytopenia of 100 × 109 L−1, the prevalence of thrombocytopenia was 6% (seven patients). No difference between primary APS and secondary APS was found. In patients who suffered from CAPS, a significant decrease from the basal count (212 ± 51 × 109 L−1) to that at the time of diagnosis (60 ± 33 × 109 L−1) was observed. The platelet count became normal again at the time of complete remission (220 ± 57 × 109 L−1). A decrease in platelet count always preceded the full clinical picture. This study shows that, in high‐risk APS patients, the prevalence of thrombocytopenia is low. A decrease in platelet count was observed in all of the patients who developed the catastrophic form of the disease. A decrease in platelet count in high‐risk APS patients should be considered a warning signal for disease progression to CAPS." @default.
• W2783176674 created "2018-01-26" @default.
• W2783176674 creator A5011151808 @default.
• W2783176674 creator A5032826393 @default.
• W2783176674 creator A5033159977 @default.
• W2783176674 creator A5046190503 @default.
• W2783176674 creator A5053242436 @default.
• W2783176674 creator A5054501484 @default.
• W2783176674 creator A5063722592 @default.
• W2783176674 creator A5069854712 @default.
• W2783176674 creator A5078780493 @default.
• W2783176674 creator A5082334430 @default.
• W2783176674 creator A5085761102 @default.
• W2783176674 date "2018-03-01" @default.
• W2783176674 modified "2023-10-09" @default.
• W2783176674 title "Thrombocytopenia in high‐risk patients with antiphospholipid syndrome" @default.
• W2783176674 cites W1498611050 @default.
• W2783176674 cites W1969171402 @default.
• W2783176674 cites W1992492269 @default.
• W2783176674 cites W1998761103 @default.
• W2783176674 cites W2004538033 @default.
• W2783176674 cites W2004868771 @default.
• W2783176674 cites W2040428956 @default.
• W2783176674 cites W2042958596 @default.
• W2783176674 cites W2054330426 @default.
• W2783176674 cites W2055282464 @default.
• W2783176674 cites W2068651023 @default.
• W2783176674 cites W2078838686 @default.
• W2783176674 cites W2105482507 @default.
• W2783176674 cites W2160483707 @default.
• W2783176674 cites W2376859318 @default.
• W2783176674 cites W2417377791 @default.
• W2783176674 cites W2621426447 @default.
• W2783176674 cites W2741232052 @default.
• W2783176674 cites W4239160933 @default.
• W2783176674 doi "https://doi.org/10.1111/jth.13947" @default.
• W2783176674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29316193" @default.
• W2783176674 hasPublicationYear "2018" @default.
• W2783176674 type Work @default.
• W2783176674 sameAs 2783176674 @default.
• W2783176674 citedByCount "37" @default.
• W2783176674 countsByYear W27831766742018 @default.
• W2783176674 countsByYear W27831766742019 @default.
• W2783176674 countsByYear W27831766742020 @default.
• W2783176674 countsByYear W27831766742021 @default.
• W2783176674 countsByYear W27831766742022 @default.
• W2783176674 countsByYear W27831766742023 @default.
• W2783176674 crossrefType "journal-article" @default.
• W2783176674 hasAuthorship W2783176674A5011151808 @default.
• W2783176674 hasAuthorship W2783176674A5032826393 @default.
• W2783176674 hasAuthorship W2783176674A5033159977 @default.
• W2783176674 hasAuthorship W2783176674A5046190503 @default.
• W2783176674 hasAuthorship W2783176674A5053242436 @default.
• W2783176674 hasAuthorship W2783176674A5054501484 @default.
• W2783176674 hasAuthorship W2783176674A5063722592 @default.
• W2783176674 hasAuthorship W2783176674A5069854712 @default.
• W2783176674 hasAuthorship W2783176674A5078780493 @default.
• W2783176674 hasAuthorship W2783176674A5082334430 @default.
• W2783176674 hasAuthorship W2783176674A5085761102 @default.
• W2783176674 hasBestOaLocation W27831766741 @default.
• W2783176674 hasConcept C126322002 @default.
• W2783176674 hasConcept C2776874634 @default.
• W2783176674 hasConcept C2777247642 @default.
• W2783176674 hasConcept C2780868729 @default.
• W2783176674 hasConcept C71924100 @default.
• W2783176674 hasConcept C89560881 @default.
• W2783176674 hasConcept C90924648 @default.
• W2783176674 hasConceptScore W2783176674C126322002 @default.
• W2783176674 hasConceptScore W2783176674C2776874634 @default.
• W2783176674 hasConceptScore W2783176674C2777247642 @default.
• W2783176674 hasConceptScore W2783176674C2780868729 @default.
• W2783176674 hasConceptScore W2783176674C71924100 @default.
• W2783176674 hasConceptScore W2783176674C89560881 @default.
• W2783176674 hasConceptScore W2783176674C90924648 @default.
• W2783176674 hasIssue "3" @default.
• W2783176674 hasLocation W27831766741 @default.
• W2783176674 hasLocation W27831766742 @default.
• W2783176674 hasOpenAccess W2783176674 @default.
• W2783176674 hasPrimaryLocation W27831766741 @default.
• W2783176674 hasRelatedWork W1523830478 @default.
• W2783176674 hasRelatedWork W2002018871 @default.
• W2783176674 hasRelatedWork W2032704876 @default.
• W2783176674 hasRelatedWork W2036904053 @default.
• W2783176674 hasRelatedWork W2038026532 @default.
• W2783176674 hasRelatedWork W2060353654 @default.
• W2783176674 hasRelatedWork W2142542018 @default.
• W2783176674 hasRelatedWork W28354593 @default.
• W2783176674 hasRelatedWork W3021363509 @default.
• W2783176674 hasRelatedWork W3152830213 @default.
• W2783176674 hasVolume "16" @default.
• W2783176674 isParatext "false" @default.
• W2783176674 isRetracted "false" @default.
• W2783176674 magId "2783176674" @default.
• W2783176674 workType "article" @default.